With their improved bioavailability and a straightforward manufacturing process, innovative lipid formulations such as softgels offer an attractive alternative to common oral solid dosage (OSD) forms like tablets and capsules, helping to streamline drug development.
As biotech and pharmaceutical organisations focus on bringing life-changing therapies to patients as quickly as possible, they must also determine the needs of their proprietary molecules and the market. Today, many companies are prioritising patient-friendly drug formats, such as oral solid dose (OSD) drugs or sterile injectables, to deliver safe and efficacious therapies to patients in need.
However, within the pharmaceutical industry, the development of new OSD drugs is fraught with challenges – one of the most significant being low bioavailability. This problem is particularly prevalent during the early stages of drug development and is a recognised reason why many drugs fail to progress beyond preclinical stages.1
Despite the risks that stem from low bioavailability, many pharma and biotech organisations continue to opt for standard OSD forms, such as tablets and capsules. In fact, there are several factors in choosing a final formulation that will offer precise control of the drug release rate, content uniformity and site of absorption. Lipid formulations, particularly softgels, offer a compelling solution to the bioavailability challenge and present several key advantages that make them worth considering from the outset.
Register your details to read more.
Download Now
No comments yet